A recently published study documented a significant anti-tumor effect of ENO-1 targeted lipid nanoparticles in an animal model of prostate cancer (Wang et al., 2018), thus opening the door for the future clinical trials not only in tumor-related pathologies, but also in other diseases, such as diabetes and cardiac hypertrophy, where ENO-1 related abnormalities are observed as well. Here, ENO1 is linked to cardiac hypertrophy.